Alan J. Gelenberg

Alan J. Gelenberg's AcademicInfluence.com Rankings

Alan J. Gelenberg

Biology

#12835

World Rank

#16338

Historical Rank

biology Degrees

Download Badge

Biology

Alan J. Gelenberg's Degrees

Doctorate Medicine University of Pennsylvania

Why Is Alan J. Gelenberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan J. Gelenberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. (2000) (1452)
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. (2000) (1290)
The Arizona Sexual Experience Scale (ASEX): reliability and validity. (2000) (821)
Gender differences in treatment response to sertraline versus imipramine in chronic depression. (2000) (634)
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder (2006) (593)
Gender differences in chronic major and double depression. (2000) (417)
Collaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysis. (2012) (412)
Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. (1989) (400)
Effectiveness of St John's wort in major depression: a randomized controlled trial. (2001) (370)
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. (2000) (280)
Pharmacologic treatment of depression during pregnancy. (1999) (255)
Risk-benefit decision making for treatment of depression during pregnancy. (2000) (247)
Lost human capital from early-onset chronic depression. (2000) (226)
THE CATATONIC SYNDROME (1976) (214)
Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. (2006) (206)
Randomized dose‐ranging pilot trial of omega‐3 fatty acids for postpartum depression (2006) (195)
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. (1998) (192)
Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. (2008) (192)
Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. (2009) (188)
Catatonic reactions to high-potency neuroleptic drugs. (1977) (182)
Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. (1992) (181)
Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. (1993) (179)
The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. (1998) (169)
Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. (2003) (155)
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. (2005) (148)
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. (2002) (138)
Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients (2005) (132)
Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. (1982) (131)
Mirtazapine substitution in SSRI-induced sexual dysfunction. (2000) (120)
Tryptophan depletion and depressive vulnerability (1999) (111)
Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. (2004) (110)
Pindolol augmentation of treatment-resistant depressed patients. (1997) (110)
The prevalence and impact of depression. (2010) (110)
Antipsychotics in bipolar disorder. (1996) (109)
Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. (1989) (107)
How fast are antidepressants? (2000) (106)
A review of the current guidelines for depression treatment. (2010) (105)
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. (2007) (92)
A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. (1988) (89)
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. (2009) (89)
Prevalence of tardive dyskinesia in an outpatient population. (1980) (89)
Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. (1995) (84)
Principles of effectiveness trials and their implementation in VA Cooperative Study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder'. (2001) (83)
Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. (2001) (81)
The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. (2008) (80)
Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology. (2010) (78)
Lecithin can suppress tardive dyskinesia. (1978) (75)
Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression (2003) (75)
Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. (2008) (74)
Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. (2002) (74)
The Practitioner’s Guide to Psychoactive Drugs (1997) (72)
Alternatives to lithium for preventive treatment of bipolar disorder. (1989) (70)
Metabolic effects of treatment with atypical antipsychotics. (2004) (69)
International consensus statement on major depressive disorder. (2010) (67)
Serum lithium levels and the outcome of maintenance therapy of bipolar disorder. (2000) (66)
Tyrosine for depression: a double-blind trial. (1990) (65)
A review of 32 cases of tardive dystonia. (1991) (64)
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. (2002) (63)
Sertraline versus imipramine to prevent relapse in chronic depression. (2001) (63)
Hazards and adverse effects of lithium. (1982) (63)
Neurotransmitter precursors for the treatment of depression. (1982) (63)
The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. (1998) (62)
The meaning of serum lithium levels in maintenance therapy of mood disorders: a review of the literature. (1989) (60)
Serum lithium levels and psychosocial function in patients with bipolar I disorder. (1996) (60)
Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. (1979) (60)
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition (2005) (59)
The pharmacologic treatment of schizophrenia: a progress report. (1983) (58)
Amoxapine — An Antidepressant With Some Neuroleptic Properties?: A Review of Its Chemistry, Animal Pharmacology and Toxicology, Human Pharmacology, and Clinical Efficacy (1981) (57)
Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with comorbid migraine. (2014) (57)
Hats Off to the Reviewers!: (Editorial) (1998) (56)
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. (2008) (56)
Bipolar disorder in women: reproductive events and treatment considerations (2005) (55)
If not now, when? (1992) (54)
The effect of dantrolene sodium on spasticity in multiple sclerosis (1973) (54)
Citalopram as adjunctive therapy in bipolar depression. (2001) (52)
Using assessment tools to screen for, diagnose, and treat major depressive disorder in clinical practice. (2010) (51)
An open trial of Omega-3 fatty acids for depression in pregnancy* (2006) (50)
Many Thanks: (Editorial) (2001) (50)
Lithium tremor. (1995) (50)
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. (2007) (50)
Tyrosine for the treatment of depression. (1980) (49)
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases (2007) (48)
Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment. (2000) (44)
Anticholinergic Effects on Memory: Benztropine versus Amantadine (1989) (43)
Assessing and treating depression in primary care medicine. (2007) (43)
Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. (1984) (43)
Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling technique. (2000) (41)
Verapamil treatment of acute mania. (1986) (40)
Sexual dysfunction secondary to depressive disorders. (1999) (39)
Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. (2002) (39)
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. (2010) (38)
Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. (1980) (36)
Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Bipolar Disorder: A Review of Biomarker and Treatment Studies. (2016) (35)
Sleep quality during euthymia in bipolar disorder: the role of clinical features, personality traits, and stressful life events (2013) (35)
Tyrosine for depression. (1982) (35)
The effect of amoxapine and imipramine on serum prolactin levels. (1981) (34)
Single case study. Amoxapine, a new antidepressant, appears in human milk. (1979) (33)
Galactorrhea and hyperprolactinemia associated with amoxapine therapy. Report of a case. (1979) (31)
Assessment of Sexual Dysfunction Using the Arizona Sexual Experiences Scale (ASEX) and Implications for the Treatment of Depression (1999) (31)
Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients (1992) (31)
Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse. (2015) (30)
Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. (2009) (28)
Alpha2-adrenergic receptors in platelet membranes of depressed patients: Increased affinity for 3H-yohimbine (1987) (27)
Rate-sensitive inhibition of ACTH release in depression. (1984) (27)
Health outcomes for people with serious mental illness: a case study. (2008) (27)
Effects of mental health benefits legislation: a community guide systematic review. (2015) (26)
The Practitioner’s Guide to Psychoactive Drugs (1991) (25)
Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. (1979) (24)
Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega‐3 plasma concentrations are altered by treatment (2015) (24)
Matching the Bipolar Patient and the Mood Stabilizer (2003) (24)
Report on efficacy of treatments for bipolar disorder. (1993) (24)
Depression is still underrecognized and undertreated. (1999) (23)
DILTIAZEM FOR TARDIVE DYSKINESIA AND TARDIVE DYSTONIA (1988) (23)
Sexual side effects of antidepressant drugs (2000) (21)
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. (2009) (21)
Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. (2011) (20)
Depression symptomatology and neurobiology. (2010) (19)
Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT Study (2013) (19)
Threats and promises. (1995) (19)
Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. (1979) (19)
Boosting serotonin in the brain: is it time to revamp the treatment of depression? (2012) (19)
Smoking cessation in patients with psychiatric disorders. (2008) (18)
A crossover study of lecithin treatment of tardive dyskinesia. (1990) (18)
Effects of two antidepressants on memory performance in depressed outpatients: a double-blind study (1984) (18)
The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. (2004) (17)
REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design. (2008) (17)
Knowing our limits (1998) (17)
Criteria for the diagnosis of catatonia. (1977) (16)
Dr. Gelenberg and Associates Reply (1979) (16)
Letter: Grams of antipsychotics? (1976) (16)
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. (2003) (16)
Treating extrapyramidal reactions: some current issues. (1987) (15)
Direct comparison of the psychometric properties of multiple interview and patient-rated assessments of suicidal ideation and behavior in an adult psychiatric inpatient sample. (2015) (15)
Anticholinergic effects on memory: benztropine vs. amantadine. (1987) (15)
Enhancement of ECT benefit by yohimbine. (1986) (15)
Smoking cessation in patients with psychiatric disorders. (2007) (15)
Recurrent Unipolar Depressions with a 48-hour Cycle: Report of a Case (1978) (15)
CDP-choline for the treatment of tardive dyskinesia: a small negative series. (1989) (15)
An open trial of maprotiline for the treatment of cocaine abuse: a pilot study. (1988) (14)
Patients with neuroleptic malignant syndrome histories: what happens when they are rehospitalized? (1989) (14)
The state of knowledge of chronic depression. (2006) (14)
Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction (2007) (14)
Consent and liability with neuroleptics: the problem of tardive dyskinesia. (1986) (13)
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. (2003) (12)
Ergoloid mesylates and ECT. (1989) (12)
Clovoxamine in the treatment of depressed outpatients: a double-blind, parallel-group comparison against amitriptyline and placebo. (1990) (12)
Renal function monitoring in patients receiving lithium carbonate. (1981) (12)
The effectiveness of generic agents in psychopharmacologic treatment. (2005) (11)
A Double‐Blind Comparison of Clovoxamine and Amitriptyline in the Treatment of Depressed Outpatients (1985) (11)
Alpha2-adrenergic receptor sensitivity in depressed patients: Relation between 3H-yohimbine binding to platelet membranes and clonidine-induced hypotension (1989) (11)
Computerized tomography in patients with tardive dyskinesia. (1976) (11)
Consultative intervention to improve outcomes of high utilizers in a public mental health system. (2004) (11)
Reconsidering Dietary Polyunsaturated Fatty Acids in Bipolar Disorder: A Translational Picture. (2016) (10)
Using physostigmine safely. (1979) (10)
Can lithium help to prevent suicide? (2001) (10)
More on Neuromuscular Side Effects of Antipsychotics (1976) (10)
New Year's Thanks: (Editorial) (2007) (10)
The Arizona Sexual Experience Scale (ASEX) (2000) (9)
TREATMENT STRATEGIES FOR DEPRESSION AND SEXUAL DYSFUNCTION (1999) (9)
345. Mirtazapine substitution in SSRI-induced sexual dysfunction (1998) (9)
Treatment of bipolar disorder: how far have we come? (1994) (8)
The effects of amitriptyline and lithium on a patient with 48-hour recurrent depressions. (1978) (8)
Introduction: The Practice of Pharmacotherapy (1983) (7)
Standing Guard: (Editorial) (1996) (7)
The American Psychiatric Association Treatment Guideline for Major Depressive Disorder: process and content (2010) (7)
Fluoxetine and sexual dysfunction. (1995) (7)
General Principles of Treatment of Extrapyramidal Syndromes (1983) (7)
Choline and lecithin administration to patients with tardive dyskinesia. (1978) (7)
346. Sequential catecholamine and 5-HT depletion in mirtazapine-treated depressives (1998) (6)
Use of choline and lecithin in the treatment of tardive dyskinesia. (1980) (6)
86-7 Double-blind crossover antidepressant study: Sertraline vs. imipramine (1997) (6)
The amobarbital interview. (1980) (6)
Biological therapies in psychiatry newsletter (1989) (6)
Amoxapine for the Treatment of Psychotically Depressed Subjects: A Pilot Study (1985) (6)
L-TYROSINE IN DEPRESSION (1980) (6)
Pregnancy, psychotropic drugs, and psychiatric disorders. (1986) (6)
Munchausen's syndrome with a psychiatric presentation. (1977) (5)
Treating the outpatient schizophrenic. (1978) (4)
Unusual lymphocyte subset distribution in some depressed patients. (1990) (4)
The state of knowledge of chronic depression. (2006) (4)
Depression, depressants, and antidepressants. (1990) (4)
Arizona Sexual Experience Scale (2016) (4)
Happy New Year!: (Editorial) (2003) (4)
The search for knowledge: developing the American Psychiatric Association's practice guideline for major depressive disorder. (2008) (4)
Complementary and alternative medicine in psychiatry. (2010) (4)
Optimizing depression treatment to increase the likelihood of remission. (2010) (3)
The effects of the Affordable Care Act on the practice of psychiatry. (2013) (3)
Maintenance drug therapy in long-term treatment of depression (1978) (3)
Antidepressants in the general hospital. (1979) (2)
Use and abuse of anticholinergic drugs in psychiatry. (1984) (2)
Major complications of neuroleptic drug use. (1994) (2)
Postmarketing surveillance: perspectives of a journal editor. (1993) (2)
Staying true to mission. (2007) (2)
The art (and blood sport) of psychopharmacology research: who has a dog in the fight? (2007) (2)
Tryptophan and 5-HT in psychiatric illness. (1996) (2)
Significant greater loss of medication from the injection site when fluphenazine (Prolixin) decanoate was injected intramuscularly as contrasted with subcutaneously. (1987) (2)
Nutrition in psychiatry: we are what we eat? (1980) (2)
Cardiac arrhythmias after psychotropic drugs. (1977) (2)
Reply to Letter to the Editor "Rapid Onset of Antidepressant Activity With Venlafaxine" (2002) (2)
Lithium efficacy and adverse effects. (1988) (2)
Pharmacologic treatment of depressive subtypes. (1988) (2)
Honoring our evidence base. (2004) (2)
Two-year placebo-controlled maintenance study to assess recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression (2007) (2)
Dr. Kornstein and Colleagues Reply (2001) (2)
CEREBRAL ATROPHY AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA (1976) (2)
Funding, conflicts, and paradigms. (2005) (1)
New antidepressant drugs: a clinical perspective. (1984) (1)
Reliability and risks of generic psychopharmacologic agents. (2005) (1)
e-Etiquette: (Editorial) (2009) (1)
Polypharmacy in Psychiatry (1995) (1)
Dr. Karasu and Colleagues Reply (1994) (1)
Tardive dyskinesia and lithium-associated nephropathy: are you liable? (1980) (1)
P.2.a.016 Prevalence and clinical correlates of pain in patients with recurrent major depressive disorder (2007) (1)
Thanks to JCP Peer Reviewers: (Editorial) (2008) (1)
Disclosing Bias: The Author Responds (2008) (1)
Closing remarks. The use of benzodiazepine hypnotics : a scientific examination of a clinical controversy (1992) (1)
Iatrogenic Sexual Dysfunction (2003) (1)
Performance improvement CME: improving outcomes in depression. (2010) (1)
FLUOXETINE AND SEXUAL DYSFUNCTION. AUTHORS' REPLIES (1995) (1)
Editorial Statement (2002) (1)
Reply to Sponsored Clinical Trials and Bias (2007) (1)
Psychiatry as a medical specialty. (1972) (1)
Treatment of bipolar depression with citalopram (2001) (1)
Is Religioness a Protective Factor against Suicide? Evaluating Suicidality and Religiousness in Psychiatric Inpatient Population Utilizing Sheehan Suicide Tracking Scale (S-STS) and Columbia Suicide Severity Rating Scale (C-SSRS) (2020) (1)
Preliminary communication Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study (2008) (1)
Antidepressants: their use in clinical practice. (1978) (1)
Editors’ Thank You: (Editorial) (2015) (1)
P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression (2006) (1)
NCDEU's golden anniversary. (2010) (1)
The Affordable Care Act and Practice in Psychiatry (2013) (0)
Recognizing and managing drug-induced depression (1992) (0)
The Journal of Clinical Psychiatry: Peer Review Circle of Honor: (Editorial) (2006) (0)
Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder (1990) (0)
Psychiatry 2013. (1993) (0)
Recurrence prevention in patients with recurrent major depression receiving 12 months of treatment with venlafaxine XR (2007) (0)
Arizona Sexual Experiences Scale (ASEX) 2000 (2012) (0)
The journal in 2004 (2004) (0)
New Drugs, Old Dilemmas (1998) (0)
Biography (1998) (0)
Circle of Honor: (Editorial) (2006) (0)
Psychotherapy in severe depression: hypothesis-generating versus hypothesis-testing. (1979) (0)
Editor's note (2000) (0)
Commentary 2 (0)
Choline and lecithin for the treatment of tardive dyskinesia [proceedings]. (1979) (0)
90-109 Predictors of response to long-term antidepressant therapy (1997) (0)
Another Year Passes: (Editorial) (2005) (0)
Imperfect drugs in an imperfect world. (1992) (0)
Reply to Letter to the Editor "Manufacturer Support and Outcome" (1999) (0)
Call for Papers From Early Career Psychiatrists: (Editorial) (2007) (0)
Overview of Drug Treatment (1990) (0)
Warning: Side Effects May Include Distorted Vision (2008) (0)
Out of the Box (2007) (0)
Apologies and Thanks to Reviewers (1998) (0)
Looking Ahead (2007) (0)
New year's greetings and gratitude. (2016) (0)
OUTCOMES OF TREATING DEPRESSION IN PREGNANCY (1999) (0)
Postpsychotic Depression-Reply (1983) (0)
Response to Marcus et al. Letter (2011) (0)
Thank You to Our Peer Reviewers. (2017) (0)
Tooting Our Horn: (Editorial) (2006) (0)
Conceptual Approach and Analytic Framework (2015) (0)
Ask the Expert: Psychopharmacology (2014) (0)
Psychiatry in the 1990s. (1991) (0)
All Good Things…. (2017) (0)
Erratum to: The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases (2012) (0)
JCP's circle of honor and peer reviewers. (2009) (0)
Annual Gratitude: (Editorial) (1999) (0)
Counterpoint : psychopharmacology supervision. (1996) (0)
Commentary: Grow the Market (2001) (0)
Conclusion on convulsions. (1985) (0)
Twenty Years at the Helm: (Editorial) (2007) (0)
Generalized anxiety disorder: an evolving concept at the border of anxiety and depression (2006) (0)
Peer review perspective for early career psychiatrists. (2009) (0)
Dr. Cole and Associates Reply (1992) (0)
Mood Disorders 2002: (492442004-001) (2002) (0)
Commentaries: Commentary 2 (1987) (0)
Editorial statement (1995) (0)
Clinical update: biological psychiatry. Conclusions on convulsions (1985) (0)
Recognition and Treatment of Depression by the Primary Care Practitioner (2020) (0)
Emergency Presentations Related to Psychiatric Medication (1984) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alan J. Gelenberg?

Alan J. Gelenberg is affiliated with the following schools: